Recruiting
Phase 1

RadProtect®

Sponsor:

Original BioMedicals Co. Ltd.

Code:

NCT02587442

Conditions

Acute Radiation Syndrome

Eligibility Criteria

Sex: All

Age: 18 - 64

Healthy Volunteers: Accepted

Interventions

RadProtect®

Study Details

Brief summary:

This is a Phase 1, non-randomized, sequential-cohort, dose escalation, open-label study designed to evaluate the safety and tolerability of RadProtect® in healthy volunteers. This study is to be conducted at two clinical centers and in conformity with Good Clinical Practice (GCP).

Conditions

Acute Radiation Syndrome

Study ID

NCT02587442

Start date

Oct, 2015

Status verified date

Oct, 2015

Primary completion date

Mar, 2016

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 64

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Each subject must be willing and able to provide written informed consent for the study
  • Healthy volunteer subjects of both genders, aged 18-64 years old, and any race/ethnicity
  • Subjects with normal blood pressure (between ranges of 120-140/60-80 mmHg) at screening and baseline
  • Subjects with a body mass index (BMI) 18-30 kg/m2
  • Men or woman of childbearing potential using adequate contraception (oral contraceptives, intrauterine device or barrier method of contraception in conjunction with spermicidal jelly, or surgically sterile) during screening, while receiving the investigational drug, and for 60 days after stopping the investigational drug
  • Female subjects of childbearing potential must have a negative urine pregnancy test at screening
  • Subjects with physiological examination and laboratory values within normal limits (CBC/differential, blood chemistry, iron, Total Iron Binding Capacity (TIBC), urinalysis, ECG and vital signs)
  • Subjects with the ability to comprehend and complete the telephone visits, screening, and site visits
  • Subjects must be able to adhere to dose and visit schedules
  • Subjects who agree to abstain from taking unauthorized medications or supplements or participating in any other clinical trial or experimental treatment during this trial.

Exclusion Criteria:

  • Subjects with any allergic reaction or sensitivity to glutamate acid, polyethylene glycol, or any component of the test article product
  • Subjects who consume > five alcoholic beverages per week
  • Subjects who are pregnant or lactating
  • Subjects who have blood (or urine) levels outside the normal range for any hepatic, renal, hematologic, lipid or coagulation parameters measured.
  • Subjects on Hormone Replacement Therapy within the past three months
  • Subjects in any other clinical trial or experimental treatment in the past three months
  • Subjects with a history of diabetes (Type 1 or Type 2 diabetes mellitus) or other endocrine disorders, hypertension, hypotension or systolic blood pressure below 80 mmHg, prior cerebrovascular accident or seizure disorder, cardiovascular, hepatic or renal disease, active cancer, hematologic disorder, thromboembolic disease, or HIV infection.

Study Design

Enrollment

27 participants

Anticipated

Intervention Model

Single group

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

experimental: RadProtect®

RadProtect® is not a full-closed micelle, and uses ferrous iron to provide linkage between PEG-b-PGA and amifostine. Transferrin and other related proteins can chelate with ferrous iron and break the micelle releasing amifostine into the blood stream.

Interventions

RadProtect®

This study will evaluate RadProtect® at sequential, escalating dose levels. Once administration is given, study subjects will be followed during 24 hours of hospitalization according to the final injection timing. All subjects will need to return to the hospital for monitoring at 7+2 days after dosing, and follow-up visits by telephone at Day 3, Day 14+2, and Day 28+2 days will need to be conducted.

Primary outcome measure

  • Safety and tolerability profile including the dose limiting toxicity (DLT) of RadProtect® intravenous injection to healthy volunteers. [ Time Frame: Day 0~ Day 28 ]

Central Contacts and Locations

Central contacts

Sandy Kan

+886-2-2697-1713sandykan@i-obm.com

San Tseng

+886-2-2697-1713santseng@i-obm.com

Locations

SNBL Clinical Pharmacology Center

Recruiting

Baltimore, Maryland, United States, 21201

Contacts

Galina Tucker

410-706-8772gtucker@snbl-cpc.com

Principal Investigator:

Mohamed Al-Ibrahim

More Information

Sponsor

Original BioMedicals Co. Ltd.

Last update posted

Oct 27, 2015

Last verified

Oct, 2015

Keywords

  • Acute Radiation Syndrome
  • ARS
  • Amifostine
  • Radio-protectants

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Original BioMedicals Co. Ltd. on 2015-10-27.